PALO ALTO, Calif., August 18, 2026
Amygdala Neurosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for ANS-858, allowing the clinical-stage biotechnology company to advance its lead candidate into human clinical development. ANS-858 is a selective, reversible and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor being initially developed to reduce pathological craving associated with alcohol use disorder and other substance use disorders. The company plans to initiate a Phase 1 clinical trial designed to support subsequent Phase 2 development across multiple potential indications. The FDA IND clearance represents an important regulatory milestone for Amygdala’s proprietary ALDH2 therapeutic platform.
ANS-858 Enters Clinical Development
ANS-858 is designed to selectively and reversibly inhibit ALDH2, an enzyme that Amygdala Neurosciences believes plays an important role in pathological craving and substance-use disease biology. The company’s development strategy is based in part on human genetic and clinical evidence linking reduced ALDH2 activity with reduced alcohol consumption. By translating this biological insight into a selective, once-daily oral therapeutic candidate, Amygdala aims to develop a potential treatment that addresses pathological craving, a major factor associated with continued substance use and relapse. The planned Phase 1 study will provide the first clinical-stage evaluation of ANS-858 and is expected to generate safety and pharmacological information needed to guide later clinical development. FDA clearance of the IND allows the company to move from preclinical development into formal clinical testing and represents a significant step for its first-in-class ALDH2 inhibitor program.
ALDH2 Platform Offers Multiple Therapeutic Opportunities
Amygdala Neurosciences has developed what it describes as a proprietary platform of selective, orally bioavailable ALDH2 inhibitors, supported by composition-of-matter intellectual property. Although ANS-858 is initially being advanced for alcohol and other substance use disorders, the company is also evaluating the potential of ALDH2 inhibition in additional therapeutic areas. One area of interest is compulsive eating and obesity, where Amygdala believes biological mechanisms associated with pathological food craving may overlap with mechanisms involved in substance use disorders. The company is evaluating ANS-858 as a potential once-daily oral therapy that could reduce pathological food cravings and potentially support long-term weight management, either as a standalone treatment or alongside GLP-1 receptor agonists. These applications remain investigational and will require additional clinical evidence to establish safety and efficacy.
Advertisement
Precision Oncology Program Expands Research Scope
Beyond addiction and metabolic disorders, Amygdala is investigating its selective ALDH2 inhibitor library in precision oncology, including a potential therapeutic approach for colorectal cancers containing APC mutations. APC is a tumor-suppressor gene with a central role in colorectal cancer biology, and the company estimates that APC mutations occur in approximately 70% of colorectal cancer cases. Amygdala believes this genetically defined population could provide an opportunity to evaluate ALDH2-targeted therapies in oncology. The company’s broader platform strategy therefore spans neurological, metabolic and cancer applications, although ANS-858’s immediate development focus remains substance use disorders. Discovery and development of the candidate have received support from NIH grants and ABMRF/The Foundation for Alcohol Research, helping advance research underlying the ALDH2 program. With FDA clearance now enabling clinical development, Amygdala plans to initiate Phase 1 testing of ANS-858 and use the resulting data to determine the candidate’s potential for further development across high-unmet-need therapeutic areas.
Source: Amygdala Neurosciences press relese
